

ORIENTAL JOURNAL OF MEDICINE AND NATURAL SCIENCES

Open Access, Peer Reviewed Journal

Scientific Journal



- Medicine
- Pharmaceuticals
- Biology
- Chemistry
- Geology
- Agriculture



+998 33 0178868



www.innoworld.net



INNOVATIVE WORLD

ORIENTAL JOURNAL OF MEDICINE AND NATURAL SCIENCES

Volume 2, Issue 2 2025

Journal has been listed in different indexings



The official website of the journal:

www.innoworld.net

Andijon-2025



NEW TREATMENT APPROACHES FOR GLAUCOMA: RECENT ADVANCEMENTS AND INNOVATIONS IN OPHTHALMOLOGY

Ashurov Abdukhamid Kholikjon Ugli

Department of general surgery, Fergana Medical Institute
of Public Health, Fergana, Uzbekistan

ashurovabduxamid0607@gmail.com

<https://orcid.org/0009-0009-0289-7441>

Abstract

Glaucoma remains a leading cause of irreversible blindness worldwide, necessitating continuous advancements in treatment strategies. This review explores the latest developments in glaucoma management, focusing on pharmacological innovations, minimally invasive glaucoma surgeries (MIGS), nanotechnology, artificial intelligence (AI), and wearable technologies. Novel drug classes, sustained-release delivery systems, and combination therapies are enhancing intraocular pressure (IOP) control while improving patient adherence. MIGS and biodegradable implants provide safer surgical alternatives with reduced complications. Nanotechnology-based drug delivery and theranostic platforms are revolutionizing treatment precision, while AI enhances diagnosis, monitoring, and patient engagement. Additionally, emerging neuroprotective strategies, including gene therapy and stem cell applications, hold promise for preserving retinal ganglion cells. These advancements collectively contribute to a more effective, personalized, and patient-centered approach to glaucoma management.

Keywords: Glaucoma, intraocular pressure, nanotechnology, minimally invasive glaucoma surgery, artificial intelligence

Introduction

Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by progressive optic neuropathy and elevated intraocular pressure (IOP). Recent advancements in ophthalmology have introduced innovative treatment approaches that aim to improve patient outcomes, reduce treatment burden, and address the limitations of traditional therapies. This response explores the latest developments in glaucoma treatment, including pharmacological innovations, minimally invasive surgical techniques, nanotechnology, and emerging therapeutic modalities.

Pharmacological Advancements in Glaucoma Management

Pharmacological treatments remain the first line of defense in glaucoma management, focusing on reducing IOP by suppressing aqueous humor production or enhancing outflow. Recent advancements in drug development have introduced novel agents and improved delivery systems to overcome the

limitations of traditional eye drops, such as poor bioavailability and nonadherence.

New Drug Classes and Targets

Researchers have identified new molecular targets for glaucoma treatment, including rho kinase inhibitors, nitric oxide donors, and endothelin receptor antagonists. These agents not only reduce IOP but also have neuroprotective effects, addressing the neurodegeneration associated with glaucoma (Giuffrida et al., 2024) (Ibraheem & Alhasan, 2024).

Sustained-Release Drug Delivery Systems

To improve patient compliance and drug bioavailability, sustained-release formulations have been developed. These include intraocular implants, injectable depot systems, and contact lenses that release medications over extended periods. For instance, liposomal drug delivery systems have shown promise in enhancing the efficacy and reducing the frequency of administration (Petrov et al., 2024) (Bose et al., 2024).

Combination Therapies

Combination therapies that target multiple pathways, such as reducing aqueous humor production and increasing outflow, are being explored. These therapies aim to achieve better IOP control with fewer side effects (Ibraheem & Alhasan, 2024) (Wang et al., 2024).

Minimally Invasive Glaucoma Surgeries (MIGS)

MIGS have revolutionized glaucoma treatment by offering safer and less invasive alternatives to traditional surgeries. These procedures are designed to reduce IOP by enhancing aqueous humor outflow while minimizing tissue trauma.

Implantable Devices

Devices such as the Xen gel stent and PRESERFLO MicroShunt have gained popularity due to their ability to lower IOP with minimal surgical intervention. These implants are designed to bypass the trabecular meshwork and facilitate aqueous outflow into the subconjunctival space (Chan et al., 2023) (Caroline et al., 2024).

Laser-Based Interventions

Selective laser trabeculoplasty (SLT) and direct selective laser trabeculoplasty (DSLT) are emerging as effective laser-based treatments. These procedures reduce IOP by enhancing trabecular outflow and are associated with fewer side effects compared to traditional laser therapies (Anthony et al., 2025) (Micheletti et al., 2024).

Biodegradable Implants

A novel polymeric minimally invasive glaucoma implant made from polycarbonate bisamide (PC-BA) has been developed. This biodegradable implant enhances aqueous humor outflow and gradually degrades over time, leaving behind a natural outflow pathway (Pereira et al., 2024).

Nanotechnology in Glaucoma Treatment

Nanotechnology has emerged as a transformative approach in glaucoma management, addressing challenges such as poor drug bioavailability and nonadherence to topical medications.

Nanostructured Drug Delivery Systems

Nanocarriers, including liposomes, nanoparticles, and niosomes, have been engineered to improve the delivery of antiglaucoma medications. These systems enhance corneal permeability, prolong drug retention, and reduce systemic side effects (Arsha & Aniyan, 2025) (Zembala et al., 2023).

Drug-Eluting Contact Lenses

Contact lenses loaded with nanomaterials are being explored as a platform for sustained drug delivery. These lenses can release medications over extended periods, improving adherence and reducing the need for frequent eye drop administration (Baghban et al., 2023).

Theranostic Platforms

Nanotechnology-based theranostic platforms combine diagnostic and therapeutic capabilities, enabling real-time monitoring of IOP and personalized drug delivery. These platforms hold promise for improving disease management and patient outcomes (Shean et al., 2024) (Baghban et al., 2023).

Artificial Intelligence in Glaucoma Care

Artificial intelligence (AI) is transforming glaucoma diagnosis, monitoring, and treatment by enhancing precision and personalization.

AI in Diagnosis and Monitoring

AI algorithms analyze retinal imaging and visual field tests to detect early signs of glaucoma. Machine learning models can also predict disease progression and identify high-risk patients (Salowe et al., 2024).

AI-Guided Surgery

Robotic surgery and AI-based guidance systems are being developed to improve the precision of glaucoma surgeries, such as MIGS and trabeculoplasty (Salowe et al., 2024).

Patient Engagement and Adherence

AI-powered platforms, including chatbots and reminder systems, are being used to educate patients and improve adherence to treatment regimens (Salowe et al., 2024).

Wearable Technologies for Glaucoma Management

Wearable devices are playing an increasingly important role in the continuous monitoring and treatment of glaucoma.

Table: Comparison of emerging glaucoma treatment modalities

Modality	Mechanism of Action	Key Advantages	Citation
Bimatoprost Implant	Sustained-release formulation reducing IOP for up to 1 year	Minimizes drop burden and improves patient compliance	(Anthony et al., 2025)

Xen Gel Stent	Subconjunctival MIGS device facilitating aqueous outflow	Minimally invasive with rapid recovery	(Chan et al., 2023)
Liposomal Drug Delivery	Targeted and sustained drug delivery via nanocarriers	Enhances bioavailability and reduces toxicity	(Bose et al., 2024)
AI-Powered Diagnostics	Machine learning models for early detection and progression monitoring	Enables early intervention and personalized treatment plans	(Salowe et al., 2024)
Stem Cell Therapy	Regeneration of trabecular meshwork and RGCs	Potential for tissue repair and vision restoration	(Ciociola et al., 2023)

Continuous IOP Monitoring

Devices such as the Sensimed Triggerfish, a smart contact lens, enable continuous IOP monitoring. These wearables provide valuable insights into IOP fluctuations and disease progression (Shean et al., 2024).

Drug Delivery via Wearables

Wearable devices, such as goggles with integrated drug delivery systems, are being explored for noninvasive IOP reduction. These systems use negative pressure to lower IOP and are designed for patient convenience (Anthony et al., 2025) (Shean et al., 2024).

Neuroprotection and Emerging Therapeutic Modalities

While IOP reduction remains the cornerstone of glaucoma management, there is growing interest in neuroprotective therapies that target retinal ganglion cell (RGC) survival.

Pharmacological Neuroprotection

Agents such as brimonidine, memantine, and nicotinamide have shown neuroprotective effects in preclinical studies. These drugs aim to prevent RGC degeneration independent of IOP reduction (Wang et al., 2024).

Stem Cell Therapy

Stem cells are being investigated for their potential to repair damaged trabecular meshwork and RGCs. These cells can differentiate into functional cells, restoring aqueous outflow and preserving vision (Ciociola et al., 2023).

Gene Therapy

Gene therapy is being explored to modify aqueous humor dynamics and protect RGCs. Viral vectors and siRNA are being used to deliver therapeutic genes to the eye (Ciociola et al., 2023).

Future Directions in Glaucoma Treatment

The future of glaucoma treatment is likely to be multifaceted, integrating advances in pharmacology, surgery, nanotechnology, and AI. Key areas of focus include:

Personalized Medicine

Advances in genomics and AI will enable personalized treatment plans tailored to individual patient needs and disease profiles (Salowe et al., 2024) (Ciociola et al., 2023).

Multimodal Therapies

Combining different treatment modalities, such as neuroprotection and IOP-lowering therapies, may provide additive or synergistic effects (Micheletti et al., 2024) (Wang et al., 2024).

Regenerative Therapies

Stem cell therapy and gene editing technologies hold promise for repairing damaged tissues and restoring vision in advanced glaucoma (Ciociola et al., 2023).

Conclusion

Recent advancements in glaucoma treatment have significantly expanded the range of options available to clinicians and patients. From novel pharmacological agents and minimally invasive surgeries to nanotechnology and AI-driven innovations, these developments are transforming the landscape of glaucoma care. As research continues to uncover new targets and technologies, the future of glaucoma management is poised to be more effective, patient-centric, and life-changing.

References:

1. Abdumuminov B.R., Eminov R.I., & Gulomov K.K. (2023). UNDERSTANDING FETAL CIRCULATION AND THE TRANSITION TO POSTNATAL CIRCULATION: SHUNTS, PLACENTA, AND CONGENITAL HEART DEFECTS. Экономика и социум, (6-1 (109)), 14-21.
2. DUE, M. A. I. N. A., & FURUNCLES, T. (2025). Universal Xalqaro Ilmiy Jurnal.
3. Gulomov, K. K., Juraev, S. B., Khamdamov, R. A., Kholikov, B. M., & Meliboev, R. A. (2025, February). IMPROVING THE TREATMENT OF COMPLICATIONS IN ENDOUROLOGICAL OPERATIONS FOR UROLITHIASIS. In INTERNATIONAL CONFERENCE ON SCIENCE, ENGINEERING AND TECHNOLOGY (Vol. 2, No. 1, pp. 31-33).
4. Gulomov, K. K., Kholikov, B. M., Sh, P. S., & Yokubov, D. Y. (2025). NEUROLOGICAL ASSESSMENT OF POSTOPERATIVE PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING (CABG). ZAMONAVIY ILM-FAN VA INNOVATSIYALAR NAZARIYASI, 2(2), 6-10.
5. Juraev, S. B., Khamdamov, R. A., Meliboev, R. A., & Yokubov, D. Y. (2025). NEW TREATMENT APPROACHES FOR PEDIATRIC UPPER GASTROINTESTINAL OBSTRUCTION IN FERGANA VALLEY. ZAMONAVIY ILM-FAN VA INNOVATSIYALAR NAZARIYASI, 2(2), 4-6.
6. Juraev, S. B., Kholikov, B. M., & Sh, P. S. (2025, February). PREVENTIVE MEASURES FOR COMPLICATIONS AFTER GASTROINTESTINAL SURGERY. In INTERNATIONAL CONFERENCE ON MULTIDISCIPLINARY STUDIES AND EDUCATION (Vol. 2, No. 1, pp. 11-12).
7. Kh, F. N., & Juraev, S. B. (2025, January). PREVENTION OF TROPHIC ULCERS IN PATIENTS WITH ATHEROSCLEROSIS OF THE FOOT ARTERIES. In INTERNATIONAL CONFERENCE ON MULTIDISCIPLINARY STUDIES AND EDUCATION (Vol. 2, No. 1, pp. 4-6).

8. Kh, F. N., & Juraev, S. B. (2025, January). PREVENTION OF TROPHIC ULCERS IN PATIENTS WITH ATHEROSCLEROSIS OF THE FOOT ARTERIES. In INTERNATIONAL CONFERENCE ON MULTIDISCIPLINARY STUDIES AND EDUCATION (Vol. 2, No. 1, pp. 4-6).
9. Khamdamov , R. (2025). ANALYSIS OF RISK FACTORS AND PREVENTIVE APPROACHES FOR MORPHOFUNCTIONAL ALTERATIONS IN NASAL ALAE DUE TO FURUNCLES. Universal International Scientific Journal, 2(1), 100–109.
10. Kholikov B.M. (2024). POSTOPERATIVE DELIRIUM: UNDERSTANDING CAUSES, RISKS, AND MANAGEMENT STRATEGIES.
11. Kholikov, B. M. (2025, February). POSTOPERATIVE DELIRIUM IN CABG PATIENTS: IDENTIFYING RISKS AND OPTIMIZING PERIOPERATIVE MANAGEMENT. In INTERNATIONAL CONFERENCE ON SCIENCE, ENGINEERING AND TECHNOLOGY (Vol. 2, No. 1, pp. 14-16).
12. Niyozbek, A. (2023). MEMBRANA POTENSIALI VA ION KANALLARI. ENG YAXSHI XIZMATLARI UCHUN, 1(6), 881-883.
13. Pirmatov, S. (2025). UROGENITAL QANDLI DIABETIK VEGETATIV NEVROPATIYANING KLINIK XUSUSIYATLARI VA DAVOSI. Universal xalqaro ilmiy jurnal, 2(1), 59-67.
14. R. A. Khamdamov. (2025). DIAGNOSTIC APPROACHES AND PREVENTION OF MORPHOFUNCTIONAL TRANSFORMATION IN NASAL ALAE FURUNCLES.
15. Ugli, A. A. K. (2024). AI-DRIVEN METAGENOMIC ANALYSIS TO UNCOVER MICROBIAL INFLUENCES ON CANCER DEVELOPMENT. ORIENTAL JOURNAL OF MEDICINE AND NATURAL SCIENCES, 1(6), 43-54.
16. Ugli, G. K. K. (2025, February). SUBACUTE SCLEROSING PANENCEPHALITIS IN KIDS: EEG & MRI TRENDS PRE-AND POST-2023. In INTERNATIONAL CONFERENCE ON SCIENCE, ENGINEERING AND TECHNOLOGY (Vol. 2, No. 1, pp. 28-30).
17. Zokirjonov, D. Z., & G'ulomov, Q. (2025). THE SIGNIFICANCE OF VITAMIN D LEVELS ON MUSCULOSKELETAL STRENGTH, ATHLETIC PERFORMANCE, AND INJURY PREVENTION. JOURNAL OF INTERNATIONAL SCIENTIFIC RESEARCH, 2(4), 419-430.
18. Ёкубов D. On differential diagnostics of spinal cord pathology of organic and functional genesis / Д. Ёкубов, А. Мазалова. – Актуальные вопросы фундаментальной медицины: сегодня и в будущем. – 2024. – № 1. – С. 36.
19. Хамраев, А., & Эминов, Р. (2023). Особенности клинического течения геморроя у детей. Актуальные вопросы детской хирургии, 1(1), 53-54.

WORLD